Habiel DM - Search Results

1

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis.

Habiel DM, Hogaboam C. Habiel DM, et al. Front Pharmacol. 2014 Jan 23;5:2. doi: 10.3389/fphar.2014.00002. eCollection 2014. Front Pharmacol. 2014. PMID: 24478703 Free PMC article. Review.

2

Heterogeneity of Fibroblasts and Myofibroblasts in Pulmonary Fibrosis.

Habiel DM, Hogaboam CM. Habiel DM, et al. Curr Pathobiol Rep. 2017 Jun;5(2):101-110. doi: 10.1007/s40139-017-0134-x. Epub 2017 May 2. Curr Pathobiol Rep. 2017. PMID: 29082111 Free PMC article.

3

Host-Microbial Interactions: Idiopathic Pulmonary Fibrosis in Technicolor.

O'Dwyer DN, Habiel D, Hogaboam C. O'Dwyer DN, et al. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1554-1556. doi: 10.1164/rccm.201701-0092ED. Am J Respir Crit Care Med. 2017. PMID: 28617080 Free PMC article. No abstract available.

4

Divergent roles for Clusterin in Lung Injury and Repair.

Habiel DM, Camelo A, Espindola M, Burwell T, Hanna R, Miranda E, Carruthers A, Bell M, Coelho AL, Liu H, Pilataxi F, Clarke L, Grant E, Lewis A, Moore B, Knight DA, Hogaboam CM, Murray LA. Habiel DM, et al. Sci Rep. 2017 Nov 13;7(1):15444. doi: 10.1038/s41598-017-15670-5. Sci Rep. 2017. PMID: 29133960 Free PMC article.

5

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M. Griffiths K, et al. Among authors: habiel dm. Sci Rep. 2018 Feb 16;8(1):3212. doi: 10.1038/s41598-018-20811-5. Sci Rep. 2018. PMID: 29453386 Free PMC article.

6

TRAIL-Dependent Resolution of Pulmonary Fibrosis.

Habiel DM, Moreira AP, Ismailoglu UB, Dunleavy MP, Cavassani KA, van Rooijen N, Coelho AL, Hogaboam CM. Habiel DM, et al. Mediators Inflamm. 2018 Jan 24;2018:7934362. doi: 10.1155/2018/7934362. eCollection 2018. Mediators Inflamm. 2018. PMID: 29670467 Free PMC article.

7

Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis.

Jones IC, Espindola MS, Narayanan R, Coelho AL, Habiel DM, Boehme SA, Ly TW, Bacon KB, Hogaboam CM. Jones IC, et al. Among authors: habiel dm. Sci Rep. 2019 Dec 24;9(1):19796. doi: 10.1038/s41598-019-56393-z. Sci Rep. 2019. PMID: 31875033 Free PMC article.

8

Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Habiel DM, Espindola MS, Coelho AL, Hogaboam CM. Habiel DM, et al. Am J Pathol. 2018 Apr;188(4):891-903. doi: 10.1016/j.ajpath.2017.12.020. Epub 2018 Feb 17. Am J Pathol. 2018. PMID: 29378172 Free PMC article.

9

Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.

Espindola MS, Habiel DM, Narayanan R, Jones I, Coelho AL, Murray LA, Jiang D, Noble PW, Hogaboam CM. Espindola MS, et al. Among authors: habiel dm. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1443-1456. doi: 10.1164/rccm.201707-1519OC. Am J Respir Crit Care Med. 2018. PMID: 29634284 Free PMC article.

10

Reply to D'Alessandro-Gabazza et al.: Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.

Espindola MS, Habiel DM, Hogaboam CM. Espindola MS, et al. Among authors: habiel dm. Am J Respir Crit Care Med. 2018 Oct 1;198(7):971-973. doi: 10.1164/rccm.201805-0972LE. Am J Respir Crit Care Med. 2018. PMID: 29979883 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page